Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors1

Radiology

Volumn 272, Issue 2, 2014, Pages 417-426

  Joo, Ijin ^a   Lee, Jeong Min ^a   Han, Joon Koo ^a   Choi, Byung Ihn ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CKD 516; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; INTRAVOXEL INCOHERENT MOTION DIFFUSION WEIGHTED MAGNETIC RESONANCE IMAGING; LIVER TUMOR; MALE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; REPRODUCIBILITY; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZOPHENONES; DIFFUSION MAGNETIC RESONANCE IMAGING; IMAGE ENHANCEMENT; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; RANDOM ALLOCATION; VALINE;

EID: 84905009178     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14131165     Document Type: Article

References (40)

1. McKeage MJ, Baguley BC. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010;116(8):1859-1871.
2. Salmon BA, Salmon HW, Siemann DW. Monitoring the treatment efficacy of the vascular disrupting agent CA4P. Eur J Cancer 2007;43(10):1622-1629. (Pubitemid 46891803)
3. Delmonte A, Sessa C. AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 2009;18(10):1541-1548.
4. Padhani AR. Functional MRI for anticancer therapy assessment. Eur J Cancer 2002;38(16):2116-2127. (Pubitemid 35223249)
5. Thoeny HC, De Keyzer F, Vandecaveye V, et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005;237(2):492-499. (Pubitemid 41507886)
6. Thoeny HC, De Keyzer F, Chen F, et al. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 2005;234(3):756-764. (Pubitemid 40250819)
7. Desar IM, ter Voert EG, Hambrock T, et al. Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging 2011;11:259-265.
8. Lavisse S, Lejeune P, Rouffiac V, et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 2008;43(2):100-111.
9. Cyran CC, von Einem JC, Paprottka PM, et al. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas. Invest Radiol 2012;47(1):49-57.
10. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96(2):189-195. (Pubitemid 46160619)
11. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986;161(2):401-407. (Pubitemid 17173295)
12. Koh DM, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol 2011;196(6):1351-1361.
13. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11(2):102-125.
14. Gschwend S, Ebert W, Schultze-Mosgau M, Breuer J. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol 2011;46(9):556-566.
15. Lewin M, Fartoux L, Vignaud A, Arrivé L, Menu Y, Rosmorduc O. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol 2011;21(2):281-290.
16. Thoeny HC, Ross BD. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010;32(1):2-16.
17. Lee J, Kim SJ, Choi H, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem 2010;53(17):6337-6354.
18. Wu H, Exner AA, Shi H, Bear J, Haaga JR. Dynamic evolutionary changes in blood flow measured by MDCT in a hepatic VX2 tumor implant over an extended 28-day growth period: time-density curve analysis. Acad Radiol 2009;16(12):1483-1492.
19. Jiang HJ, Lu HB, Zhang ZR, et al. Experimental study on angiogenesis in a rabbit VX2 early liver tumour by perfusion computed tomography. J Int Med Res 2010;38(3):929-939.
20. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988;168(2):497-505.
21. Iellamo F, Legramante JM, Raimondi G, Castrucci F, Massaro M, Peruzzi G. Evaluation of reproducibility of spontaneous baroreflex sensitivity at rest and during laboratory tests. J Hypertens 1996;14(9):1099-1104. (Pubitemid 26329287)
22. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188(6):1622-1635. (Pubitemid 46866868)
23. Thoeny HC, De Keyzer F. Extracranial applications of diffusion-weighted magnetic resonance imaging. Eur Radiol 2007;17(6):1385-1393. (Pubitemid 46767586)
24. Ricart AD, Ashton EA, Cooney MM, et al. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;68(4):959-970.
25. Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 2006;12(13):4090-4094. (Pubitemid 44078097)
26. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21(23):4428-4438. (Pubitemid 46621821)
27. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99(1):1-6. (Pubitemid 34273190)
28. Watanabe S, Nitta N, Ohta S, et al. Comparison of the anti-tumor effects of two platinum agents (miriplatin and fine-powder cisplatin). Cardiovasc Intervent Radiol 2012;35(2):399-405.
29. Hoekstra LT, van Lienden KP, Verheij J, van der Loos CM, Heger M, van Gulik TM. Enhanced tumor growth after portal vein embolization in a rabbit tumor model. J Surg Res 2013;180(1):89-96.
30. Hsu CY, Shen YC, Yu CW, et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 2011;55(4):858-865.
31. Chang YC, Yu CJ, Chen CM, et al. Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imaging 2012;36(2):387-396.
32. Hirashima Y, Yamada Y, Tateishi U, et al. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 2012;130(10):2359-2365.
33. Akisik MF, Sandrasegaran K, Bu G, Lin C, Hutchins GD, Chiorean EG. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology 2010;256(2):441-449.
34. Sigmund EE, Vivier PH, Sui D, et al. Intravoxel incoherent motion and diffusion-tensor imaging in renal tissue under hydration and furosemide flow challenges. Radiology 2012;263(3):758-769.
35. Federau C, Maeder P, O'Brien K, Browaeys P, Meuli R, Hagmann P. Quantitative measurement of brain perfusion with intravoxel incoherent motion MR imaging. Radiology 2012;265(3):874-881.
36. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10(2):415-427. (Pubitemid 38173977)
37. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2001;2(2):82-87. (Pubitemid 33585919)
38. Dóczi T, Schwarcz A. Correlation of apparent diffusion coefficient and computed tomography density in acute ischemic stroke. Stroke 2003;34(5):e17-e18; author reply e17-e18.
39. Wang H, Marchal G, Ni Y. Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer. World J Radiol 2011;3(1):1-16.
40. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66(24):11520-11539. (Pubitemid 46094158)